PFS Stock Recent News

I use YCharts' Value Score and Ben Graham Formula to identify large-cap stocks offering strong value relative to profits, assets, and dividends. Eighteen of twenty-four 'safer' lowest-priced Dividend Dogs of the GVAS are fair-priced and ready to buy for income-focused investors. Top ten GVAS stocks are projected to deliver 17.99% to 68.74% net gains by May 2026, with average risk 29% below the market.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer.

Scoping Report to define environmental programs for ML Application HIGHLIGHTS Recent Tunkillia OSS confirms large-scale gold project generating $2.7bn operating free cash1 Barton Gold fully funded to accelerate key long-lead PFS and Mining Lease programs ERIAS engaged to lead environmental assessments for future Mining Lease applications ADELAIDE, AUSTRALIA / ACCESS Newswire / May 7, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to announce the acceleration of long-lead feasibility work programs for its South Australian Tunkillia Gold Project (Tunkillia) following the recent publication of Tunkillia's Optimised Scoping Study (OSS). The Tunkillia OSS has identified a compelling large-scale operation with (at an A$5,000/oz gold price):1 total payable metal: 942koz gold and ~2Moz silver avg annual production: ~120koz gold and ~250koz silver operating free cashflow: A$2.7 billion Net Present Value (NPV7.5%): A$1.4 billion Internal Rate

Supports Bulldog Capital Nominees to Tejon Ranch Board of Directors PALO ALTO, Calif. , May 7, 2025 /PRNewswire/ -- Glenbrook Capital Management ("Glenbrook" or "we"), long-time shareholders of Tejon Ranch Co. (NYSE:TRC) ("Tejon" or the "Company") and owners of approximately 1.1% of outstanding shares of the Tejon, today issued the following statement outlining their intention to vote FOR Item #4 to allow Tejon shareholders owning a combined 10% of outstanding shares to call a special meeting of shareholders and FOR Bulldog Capital's state of nominees ("Bulldog's Slate") to the Tejon Board of Directors (the "Board"), at the May 13 Tejon Annual Meeting of Shareholders (the "Annual Meeting").

After-tax NPV 5% of US$1,353 million at approx. spot of US$3,200 gold price After-tax NPV 5% of US$603 million at US$2,200 base-case gold price A compelling after-tax IRR of 72% at US$3,200 gold and 40% at US$2,200 base case gold price AISC of US$1,111/oz After-tax payback period of 2 years The Company has received a positive legal opinion on status of the Castelo de Sonhos Permit, which remains valid and in good standing Scottsdale, Arizona--(Newsfile Corp. - May 5, 2025) - TriStar Gold Inc. (TSXV: TSG) (OTCQB: TSGZF) ("TriStar" or the "Company), is pleased to announce a prefeasibility study ("Study") update for the Company's Castelo de Sonhos gold project in southern Pará State, Brazil by GE21 Consultoria Mineral Ltda ("GE21") of Belo Horizonte, Brazil.

Provident Financial Services, Inc. (NYSE:PFS ) Q1 2025 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Adriano Duarte - IR Officer Anthony Labozzetta - President & CEO Thomas Lyons - Senior Executive Vice President & CFO Conference Call Participants Tim Switzer - KBW Mark Fitzgibbon - Piper Sandler Feddie Strickland - Hovde Group Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.

Although the revenue and EPS for Provident Financial (PFS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Provident Financial (PFS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.43 per share a year ago.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced o.

Provident Financial (PFS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.